Significance of DNA polymerase delta catalytic subunit p125 induced by mutant p53 in the invasive potential of human hepatocellular carcinoma

Oncology

Volumn 79, Issue 3-4, 2011, Pages 229-237

  Sanefuji, Kensaku ^a   Taketomi, Akinobu ^a   Iguchi, Tomohiro ^a   Sugimachi, Keishi ^a   Ikegami, Toru ^a   Yamashita, Yo Ichi ^a   Gion, Tomonobu ^a   Soejima, Yuji ^a   Shirabe, Ken ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Invasion; p53; POLD1

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; DNA DIRECTED DNA POLYMERASE DELTA; INDOCYANINE GREEN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN; PROTEIN P125; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INDUCED MUTATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX RATIO; TISSUE DIFFERENTIATION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL MOVEMENT; DNA POLYMERASE III; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952101678     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322374     Document Type: Article

References (40)

1. Hubscher U, Maga G, Spadari S: Eukaryotic DNA polymerases. Annu Rev Biochem 2002; 71: 133-163. (Pubitemid 34800217)
2. Johnson A, O'Donnell M: Cellular DNA rep-licases: components and dynamics at the replication fork. Annu Rev Biochem 2005; 74: 283-315. (Pubitemid 40995509)
3. Lydeard JR, Jain S, Yamaguchi M, Haber JE: Break-induced replication and telomerase-independent telomere maintenance require pol32. Nature 2007; 448: 820-823. (Pubitemid 47266343)
4. Maloisel L, Fabre F, Gangloff S: DNA poly-merase delta is preferentially recruited dur-ing homologous recombination to promote heteroduplex DNA extension. Mol Cell Biol 2008; 28:1373-1382. (Pubitemid 351214138)
5. Kunkel TA, Bebenek K: DNA replication fi-delity. Annu Rev Biochem 2000; 69:497-529.
6. Pavlov YI, Shcherbakova PV, Rogozin IB: Roles of DNA polymerases in replication, repair, and recombination in eukaryotes. Int Rev Cytol 2006; 255: 41-132. (Pubitemid 44914172)
7. Garg P, Burgers PM: DNA polymerases that propagate the eukaryotic DNA replication fork. Crit Rev Biochem Mol Biol 2005; 40: 115-128. (Pubitemid 40604979)
8. Liu L, Mo J, Rodriguez-Belmonte EM, Lee MY Identification of a fourth subunit of mammalian DNA polymerase delta. J Biol Chem 2000; 275: 18739-18744. (Pubitemid 30422833)
9. Zhao L, Chang LS: The human POLD1 gene: identification of an upstream activator se-quence, activation by sp1 and sp3, and cell cycle regulation. J Biol Chem 1997; 272: 4869-4882. (Pubitemid 27090035)
10. Li B, Lee MY Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppres-sor and sp1. J Biol Chem 2001; 276:29729-29739.
11. Harris CC: P53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996; 17:1187-1198. (Pubitemid 26196329)
12. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-49.
13. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. (Pubitemid 46890874)
14. Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Shuto T, Hirohashi K: Surgical treatment for hepatocellular carcinoma detected after suc-cessful interferon therapy. Surg Today 2007; 37: 285-290. (Pubitemid 46496275)
15. Shirabe K, Takenaka K, Taketomi A, Kawahara N, Yamamoto K, Shimada M, Sugimachi K: Postoperative hepatitis status as a sig-nificant risk factor for recurrence in cir-rhotic patients with small hepatocellular carcinoma. Cancer 1996; 77:1050-1055. (Pubitemid 26080893)
16. Sanefuji K, Kayashima H, Iguchi T, Sugimachi K, Yamashita Y, Yoshizumi T, Soejima Y, Nishizaki T, Taketomi A, Maehara Y: Char-acterization of hepatocellular carcinoma de-veloped after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol 2009; 99: 32-37.
17. Ueno M, Uchiyama K, Ozawa S, Nakase T Togo N Hayami S, Yamaue H: Prognostic im-pact of treatment modalities on patients with single nodular recurrence of hepatocellular carcinoma. Surg Today 2009; 39:675-681.
18. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Ji Y Huang LW, Jia HL, Sun HC, Wang L: P53 immunohistochemical scoring: an independent prognostic marker for pa-tients after hepatocellular carcinoma resec-tion. World J Gastroenterol 2002; 8:459-463. (Pubitemid 34692742)
19. Caruso ML, Valentini AM: Overexpression of p53 in a large series of patients with hepato-cellular carcinoma: a clinicopathological cor-relation. Anticancer Res 1999; 19:3853-3856.
20. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY Expression of p53 gene in 184 unifocal hepa-tocellular carcinomas: association with tu-mor growth and invasiveness. Cancer Res 1993; 53: 4691-4694.
21. Ng IO, Lai EC, Chan AS, So MK: Overex-pression of p53 in hepatocellular carcino-mas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995; 10: 250-255.
22. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-679. (Pubitemid 20089305)
23. Baas IO, Mulder JW, Offerhaus GJ, Vogel-stein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorec-tal neoplasms. J Pathol 1994; 172:5-12. (Pubitemid 24074995)
24. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K: Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993; 53: 2884-2887. (Pubitemid 23180531)
25. Goldsby RE, Hays LE, Chen X, Olmsted EA, Slayton WB, Spangrude GJ, Preston BD: High incidence of epithelial cancers in mice deficient for DNA polymerase delta proof-reading. Proc Natl Acad Sci USA 2002; 99: 15560-15565. (Pubitemid 35403973)
26. Sigurdson AJ, Hauptmann M, Chatterjee N Alexander BH, Doody MM, Rutter JL, Struewing JP: Kin-cohort estimates for fa-milial breast cancer risk in relation to vari-ants in DNA base excision repair, BRCA1 in-teracting and growth factor genes. BMC Cancer 2004; 4: 9.
27. Weber F, Shen L, Fukino K, Patocs A, Mutter GL, Caldes T, Eng C: Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as poten-tial landscaper for neoplastic initiation. Am J Hum Genet 2006; 78: 961-972. (Pubitemid 43787688)
28. Venkatesan RN, Treuting PM, Fuller ED, Goldsby RE, Norwood TH, Gooley TA, Ladi-ges WC, Preston BD, Loeb LA: Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instabil-ity and accelerates tumorigenesis. Mol Cell Biol 2007; 27:7669-7682. (Pubitemid 350033672)
29. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, Harris CC: P53 gene muta-tion and integrated hepatitis B viral DNA se-quences in human liver cancer cell lines. Carcinogenesis 1993; 14:987-992. (Pubitemid 23169159)
30. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M: Abnormal struc-ture and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 1973-1977.
31. May E, Jenkins JR, May P: Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene. Oncogene 1991; 6: 1363-1365. (Pubitemid 21924232)
32. Liver Cancer Study Group of Japan: General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 2. Tokyo, Kane-hara, 2003.
33. Itoh S, Maeda T, Shimada M, Aishima S, Shi-rabe K, Tanaka S, Maehara Y: Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 2004; 10:2812-2817. (Pubitemid 38509160)
34. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM: Interaction of the human papillomavirus type 16 E6 oncopro-tein with wild-type and mutant human p53 proteins. J Virol 1992; 66: 5100-5105.
35. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992; 70:523-526.
36. Varnavski AN, Young PR, Khromykh AA: Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based kunjin virus replicon vectors. J Virol 2000; 74:4394-4403. (Pubitemid 30214447)
37. Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, Balestrieri MR, Colombo M: High rates of hepatocellu-lar carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001; 34: 523-528. (Pubitemid 32786643)
38. Vojtesek B, Bartek J, Midgley CA, Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclo-nal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-244.
39. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K: Cancer-derived p53 mutants suppress p53-target gene ex-pression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007; 35: 2093-2104. (Pubitemid 47061674)
40. Harbour JW, Dean DC: Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000; 2:E65-E67.